Treatment(s) now being considered-Chemotherapy Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Chemotherapy Posts on Medivizor

What is the best timing for chemotherapy after surgery in patients with early-stage breast cancer?

What is the best timing for chemotherapy after surgery in patients with early-stage breast cancer?

Posted by on Jul 11, 2021 in Breast cancer | 0 comments

In a nutshell This study looked at the timing of chemotherapy (CT) after surgery in the treatment of early breast cancer (BC). The authors found that CT given within 31 days after surgery may improve survival in patients with triple-negative (TN) BC.  Some background BC is one of the most common types of cancer found in women. There are...

Read More

FOLFIRINOX before pre-surgery treatment can improve the outcomes of patients with rectal cancer

FOLFIRINOX before pre-surgery treatment can improve the outcomes of patients with rectal cancer

Posted by on Jun 6, 2021 in Colorectal cancer | 0 comments

In a nutshell The aim of this study was to investigate FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, and fluorouracil) before pre-surgery chemoradiotherapy (CRT) for patients with rectal cancer (RC). The study found that FOLFIRINOX given before CRT and surgery improved the outcomes of these patients. Some background RC can be treated with...

Read More

Comparing the effectiveness of different chemotherapy regimens after surgery in early stage breast cancer

Comparing the effectiveness of different chemotherapy regimens after surgery in early stage breast cancer

Posted by on Apr 21, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of current chemotherapy regimens for treatment in patients with early-stage breast cancer (BC). The data showed that the current treatment regimens have similar effectiveness. Some background BC is classified into different subtypes depending on the presence or...

Read More

Is nab-paclitaxel a better option than standard solvent-based taxanes for women with breast cancer?

Is nab-paclitaxel a better option than standard solvent-based taxanes for women with breast cancer?

Posted by on Feb 28, 2021 in Breast cancer | 0 comments

In a nutshell This study explored whether nanoparticle albumin-bound (nab) paclitaxel (Abraxane) is more efficient as chemotherapy before surgery compared to solvent-based (sb) taxanes in patients with breast cancer. The authors found that nab-paclitaxel was able to improve the outcomes of these patients. Some background Breast cancer...

Read More

What is the optimal duration of chemotherapy after surgery for patients with stage III colon cancer?

What is the optimal duration of chemotherapy after surgery for patients with stage III colon cancer?

Posted by on Feb 7, 2021 in Colorectal cancer | 0 comments

In a nutshell This trial looked at the length of adjuvant chemotherapy (AC; chemotherapy after surgery) for patients with stage III colon cancer. The authors found that 3 months of AC resulted in similar survival with reduced levels of toxicity, and cost compared to 6 months.  Some background AC has been standard care for patients with...

Read More

Is chemotherapy beneficial for the treatment of patients with T1bN0M0 triple-negative breast cancer?

Is chemotherapy beneficial for the treatment of patients with T1bN0M0 triple-negative breast cancer?

Posted by on Jan 31, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the benefits of chemotherapy after surgery in patients with T1bN0M0 triple-negative breast cancer (TNBC). The data showed that chemotherapy after surgery resulted in similar outcomes as patients who did not undergo chemotherapy. Some background Triple-negative breast cancer (TNBC) is a subtype of breast...

Read More

Bevacizumab combined with first-line chemotherapy for metastatic colorectal cancer in a real-world setting

Bevacizumab combined with first-line chemotherapy for metastatic colorectal cancer in a real-world setting

Posted by on Jan 19, 2021 in Colorectal cancer | 0 comments

In a nutshell This article looked at the effectiveness of bevacizumab (Avastin) with chemotherapy for metastatic colorectal cancer (mCRC) in a real-world setting. The authors found that the addition of bevacizumab to chemotherapy regimens provides survival benefits in patients who cannot undergo curative local treatment. Some background...

Read More

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Posted by on Jan 17, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of GDP (gemcitabine, dexamethasone, and cisplatin) and ICE (ifosfamide, carboplatin, and etoposide) regimens as salvage therapy in patients with relapsed/refractory aggressive lymphoma. The data showed that both the GDP and ICE regimens are suitable options for relapsed/refractory...

Read More

Pembrolizumab plus chemotherapy can delay progression of advanced triple negative breast cancer

Pembrolizumab plus chemotherapy can delay progression of advanced triple negative breast cancer

Posted by on Dec 31, 2020 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of pembrolizumab (Keytruda) plus chemotherapy in patients with inoperable or metastatic triple-negative breast cancer. The data showed that the combination is effective in improving progression-free survival in these patients. Some background Triple-negative breast cancer (TNBC)...

Read More

A shorter mFOLFOX/CAPOX treatment is effective and safe for patients with stage 2 colon cancer

A shorter mFOLFOX/CAPOX treatment is effective and safe for patients with stage 2 colon cancer

Posted by on Dec 26, 2020 in Colorectal cancer | 0 comments

In a nutshell This study compared 3 and 6 months of oxaliplatin (Eloxatin)-based chemotherapy in stage 2 colon cancer. Researchers suggested that the 3-month treatment might be a good and safer option for these patients. Some background Colorectal cancer is the third most common cancer diagnosed in both men and women in the US. Chemotherapy after...

Read More